NovioPonics enters the first Startupbootcamp Smart Materials Program for crop protection

Startupbootcamp Smart Materials is Europe’s first business accelerator for materials.

March 31, 2015

NovioPonics won the selection of starting the Startup Bootcamp Smart Materials at Brightlands Chemelot Campus, the Netherlands.

Novioponics is active in crop protection and aims at reducing the use of pesticides. NovioPonics applies a hydrogel which is liquid in the cold state and, once heated, gelates. Due to the gel, the pesticides are applied evenly over the plant. Also, the drip, leak of pesticides in the soil, is considerably less (<50%), says Linde Zhou, CEO of Novioponics.


Cutting in half the use of crop chemicals through an innovative dosing system.


NovioPonics BV:
Linde Zhou, CEO
tel. +31 24 7114278

Nanomedicine for periodontal disease

February 3, 2015 (Radboud University)

Periodontal diseases, including periodontitis and peri-implantitis, are oral infections associated with inflammation-mediated loss of the periodontal ligament (PDL) and/or supporting alveolar bone, which finally results in tooth/implant loss. Clinical treatment of periodontal diseases is very costly and time consuming.

Prof.dr. John Jansen and Dr. Fang Yang, Department Biomaterials, Radboud University Medical Center team up with Prof.dr. Alan Rowan, Cluster Molecular Chemistry, Radboud University to develop a more efficient therapy. They explore the efficacy of an injectable biomolecule delivery system, which includes a nanofibrous polyisocyanide gel, polyglycolic-lactid acid microspheres and pro-resolving agents to resolve inflammation.

The polyisocyanide gel – discovered by Rowan – stiffens in a warm environment .

The knowledge obtained from this project named BioPerio can also be used for treatment of other inflammatory diseases, including peritonitis, dermal inflammation and rheumatoid arthritis.

Technology Foundation STW granted the BioPerio-project 350.000 euro recently. BioPerio is part of the Radboud Nanomedicine Alliance.


In another project, the use of the supergel for wound dressing will be the topic of research.

Source: Radboud University

Secmatix and NovioTech are partners in this project with their own contributions

Supergel wound dressing

Two million euro grant for supergel wound dressing

Date of news: 2 February 2015 (Radboud University)

A biomimetic hydrogel for smart wound dressings will be made on basis of a super gel from Radboud University with the help of a large grant from ZonMW.

Imagine spraying on a smart liquid wound dressing, which immediately gelates, covering the wound, filling even deep ulcer wounds. A dressing which has nanosized pores which allows water to escape yet prevents bacteria from getting in, yet is smart and triggers rapid healing, stimulating the cells to grow in an ordered fashion preventing scarring. A smart material, which mimics the extracellular matrix found in your body aiding wound repair, yet can be easily applied and removed. This ideal dream material is at hand.

Molecular chemist Prof.dr. Alan Rowan from Radboud University immediately understood the biomedical promises of the ‘super gel’ he and his group discovered in 2013. With a two million euroZonMW 2-Treat Public-Private Partnership grant an application will be developed. Rowan will form a consortium with Prof.dr. John Jansen from Radboudumc, who is specialized in biomaterials and Prof.dr. Esther Middelkoop plastic and reconstructive surgeon at Free University Medical Center Amsterdam and the Dutch Burns Foundation Heli-X, BV to turn his hydrogel into biomimetic active wound dressings for direct application by the clinicians in burns and deep ulcer wounds.

ZonMW is the Netherlands Organisation for Health Research and Development.

The smart wound dressings project is part of Radboud Nanomedicine Alliance.

In another project, the use of the supergel for periodontal disease wil be considered.

Source: Radboud University

Secmatix and NovioTech are partners in this project with their own contributions.

NovioSense Non-Invasive Tear Glucose Sensor Patent

NIJMEGEN, Netherlands–(BUSINESS WIRE)–NovioSense BV today announced the issuance by the European Patent Office of a patent that discloses a wireless flexible spring like sensor for detection of glucose levels in tear fluid. This invention contributes to the non-invasive near field communications (NFC) trend sweeping the medical device industry.

“The patent claims our proprietary technology platform that allows wireless measurement of biomarker levels utilizing an electro active redox enzyme system combined with near field communications found in many smart phones”

The patent with publication number EP2699690B1 is for a medical device making use of a flexible wireless sensor system based on an electrochemical cell utilizing a hollow coil electrode.

“The patent claims our proprietary technology platform that allows wireless measurement of biomarker levels utilizing an electro active redox enzyme system combined with near field communications found in many smart phones” said Dr. Christopher Wilson CEO, NovioSense BV. “This first patent award is a significant value creation step for NovioSense and is currently being utilized in our tear glucose sensor.” he said.

The granting of this patent is a step forward in the commercialization of a tiny sensor that sits in the lower eyelid to continuously measure glucose levels in tears for use in the treatment of type 1 diabetes. It further protects the NovioSense technology for use of the flexible electrochemical sensor or the measurement of a wide range of small molecule biomarkers found in many biological fluids inside and outside of the body including blood, saliva and urine.

“With the introduction of contactless communications capable of powering passive sensors into mainstream smartphones the opportunities to deliver exciting products for diabetics and glucose management will continue to grow. Today non-invasive glucose measurement is becoming increasingly competitive. We have found ourselves competing with multinational technology and pharmaceutical companies such as Google and Novartis” said Dr. Wilson. “NovioSense is very active in the space of connected medical sensors and we believe we are leading the way to non-invasive micro sensors. We are actively seeking ways to exploit our technology base in new application domains.” he said.

About NovioSense BV

NovioSense BV was founded in July 2012 as a joint venture between NovioTech BV in Nijmegen (NL) and Fraunhofer IMS in Duisburg (DE). The company has raised financing from regional seed fund PPM Oost and Health Innovation Fund as well as in the form of a European Subsidy as part of the InterReg IV A Telemedicine Project. The aim of the company is to develop a clinical prototype device to prove the principle of glucose measurement in tears and to seek strategic partnerships to bring the technology to the market. NovioSense is entering clinical trials of its sensor systems for tolerance and expects to address efficacy in 2015 with market introduction to commence in 2018. The company is actively seeking strategic partnerships with medical device and smartphone manufactures to accelerate its path to market and to explore the application of its technology platform into new directions. For further information on NovioSense BV, please visit For media and images please visit


NovioSense BV:
Dr. Christopher Wilson CEO
tel. +31 6 83 84 34 76

Sinensis Life Sciences acquires Spinnovation

Press Release Sinensis – Acquisition Spinnovation – 19 September 2014

Sinensis Life Sciences B.V., Leiden, the Netherlands, announces today that it has acquired Spinnovation Holding B.V., Oss, the Netherlands, a contract research organisation specialised in the application of nuclear magnetic resonance (NMR) techniques in the pharmaceutical and biotechnological market.
September 19, 2014, Leiden, Oss, the Netherlands

Spinnovation was one of the participations in the Hanssen/Tweehuysen portfolio.

NovioSense glucose sensor and Google

Last Thursday (January 16, 2014) Google unveiled a contact lens that monitors glucose levels in tear fluid. According to Google it will take at least five years to reach consumers.

NovioSense develops a sensor based on the same substrate as Google’s (tear fluid) and NovioTech thinks that Google has a very interesting technology. However, NovioTech believes that the technology of its spin-off company NovioSense has advantages. NovioSense has, together with the Fraunhofer IMS institute in Duisburg, Germany, developed a first working prototype of its glucose sensor for measuring glucose concentrations in tear fluid.

See the NovioSense website here for more information on the NovioSense technology.

NovioPonics BV, novel additives in pesticides

NovioTech BV is working on applications of the thermo-reversible hydrogel NovioHelix®  in horticulture. In January 2014 NovioTech has founded a new company, NovioPonics BV, which entirely focuses on the development of products and intellectual property on this domain.

After proof of principle research by NovioTech, which resulted in positive outcome, NovioTech has raised initial funding from the StartLife program in Wageningen, the Netherlands, to perform further proof of concept experiments, develop intellectual property and products. NovioPonics collaborates with the Wageningen University and is one of the portfolio companies (a 100%) of Hanssen/Tweehuysen, owners of NovioTech .

You can find more information on the NovioHelix® gel: see the NovioHelix button, above.


NovioPonics BV:
Linde Zhou, CEO
tel. +31 24 7114278

NovioTech is partner in the Marie Curie project iTERM for regenerative medicine

From the iTERM website:



Welcome to the iTERM website

iTERM is a Marie Curie Initial Training Network (ITN) on
Training scientists to develop and Image materials for Tissue Engineering and Regenerative Medicine.

It is a four year project funded by the European Commission and bringing together 6 renowned research institutes and 2 SME, each specialized in different aspects of tissue engineering. The overall objective of this project is to provide a training network for scientists who will develop new materials and implants for the bio-engineering of soft tissue (skin, urogenital) and hard (bone) tissue as well as state-of-the-art novel multimodality visualization procedures to monitor the behaviour of implants.

iTERM will recruit 12 PhD students (Early-Stage-Researchers, ESR) and 1 postdoc (Experienced Researcher, ER) at 8 partner organisations in 6 European countries. The hosts organizations are:

  1. Radboud University Nijmegen Medical Centre, The Netherlands
  2. University of  Zürich, Switzerland
  3. University of Hull, United Kingdom
  4. Uppsala University, Sweden
  5. Warsaw University of Technology, Poland
  6. Nano4Imaging GmbH, Aachen, Germany
  7. NovioTech BV, Nijmegen, The Netherlands
  8. University Hospital Basel, Switzerland

The iTERM programme will start on October 1, 2013. Through this website, we will keep you informed about the progress of our research and training network.

Dr. Egbert Oosterwijk
Coordinator iTERM
Associate Professor of Experimental Urology



NovioTech BV:
Joan Simó Padial
tel. +31 24 7114278

Opening lecture ‘Super gel’ at the MicroNano 4FutureProfit event

Wednesday, June 19th 2013, 13:00 – 17:30h, FHI, Leusden

13.00 – 13.30h Opening lecture ‘Super gel’

Alan Rowan – Professor Molecular Materials at Radboud University Nijmegen Medical CentreTurning a bucket full of water into gel with one gram of powder?

Professor molecular materials Alan Rowan depicts a fascinating development. Along with favourable comments, the scientific journal Nature spent several pages on his study. It not only gained scientific attention, read the article in the NRC here.

Bringing Technologies to the Market